Docoh
Loading...

HALO Halozyme Therapeutics

GRANT
Utility
PH20 polypeptide variants, formulations and uses thereof
20 Jul 21
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 25 Jun 20
GRANT
Utility
PH20 polypeptide variants, formulations and uses thereof
22 Jun 21
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 19 Mar 20
GRANT
Utility
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
26 Jan 21
Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies.
Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
Filed: 2 Apr 19
GRANT
Utility
PH20 polypeptide variants, formulations and uses thereof
14 Dec 20
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 1 Aug 16
GRANT
Utility
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
16 Mar 20
The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies.
Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
Filed: 22 Feb 18
  • 1
Patents are sorted by USPTO publication date, most recent first